DSNKY Stock - Daiichi Sankyo Company, Limited
Unlock GoAI Insights for DSNKY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.89T | $1.60T | $1.28T | $1.04T | $962.52B |
| Gross Profit | $1.47T | $1.19T | $914.95B | $691.56B | $624.23B |
| Gross Margin | 78.0% | 74.1% | 71.6% | 66.2% | 64.9% |
| Operating Income | $331.93B | $211.59B | $120.58B | $73.03B | $63.80B |
| Net Income | $295.76B | $200.73B | $109.19B | $66.97B | $75.96B |
| Net Margin | 15.7% | 12.5% | 8.5% | 6.4% | 7.9% |
| EPS | $155.96 | $104.69 | $56.96 | $34.94 | $39.17 |
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 25th 2023 | Jefferies | Downgrade | Hold | - |
Earnings History & Surprises
DSNKYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 23, 2026 | — | — | — | — |
Q1 2026 | Jan 29, 2026 | — | — | — | — |
Q4 2025 | Oct 31, 2025 | — | $0.00 | — | — |
Q3 2025 | Jul 29, 2025 | — | $0.32 | — | — |
Q2 2025 | Apr 23, 2025 | — | $0.32 | — | — |
Q1 2025 | Jan 29, 2025 | — | $0.21 | — | — |
Q4 2024 | Oct 31, 2024 | — | $0.22 | — | — |
Q3 2024 | Jul 31, 2024 | — | $0.28 | — | — |
Q2 2024 | Apr 25, 2024 | — | $0.13 | — | — |
Q1 2024 | Feb 29, 2024 | — | $0.25 | — | — |
Q3 2023 | Sep 30, 2023 | — | $0.14 | — | — |
Q2 2023 | Jun 30, 2023 | — | $0.21 | — | — |
Q1 2023 | Mar 31, 2023 | — | $0.09 | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.11 | — | — |
Q3 2022 | Sep 30, 2022 | — | $0.14 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.07 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.12 | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.14 | — | — |
Q3 2021 | Sep 30, 2021 | — | $0.13 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.17 | — | — |
Latest News
Daiichi Sankyo And AstraZeneca's DATROWAY EU Application Validated For First Line Metastatic TNBC Without Immunotherapy Option Supported By TROPION-Breast02 OS And PFS Improvements
📈 PositiveDaiichi Sankyo Says First Patient Dosed In Randomization Phase Of DESTINY-Ovarian01 Phase 3 Trial Evaluating ENHERTU, Jointly Developed, Commercialized By Daiichi And AstraZeneca, In Patients With HER2 Expressing Advanced Ovarian Cancer
📈 PositiveReported Earlier, Daiichi Sankyo And AstraZeneca Announce First Patient Dosed In DESTINY-Lung06 Phase 3 Trial Of ENHERTU As First-Line Therapy In HER2 Overexpressing Metastatic Non-Squamous NSCLC
📈 PositiveAstraZeneca, Daiichi Sankyo's DATROWAY Showed Statistically Significant, Clinically Meaningful Improvement For Dual Primary Endpoints Of Overall Survival, Progression-Free Survival In TROPION-Breast02 Phase 3 Study For Recurrent Inoperable Or Metastatic Triple-negative Breast Cancer
📈 PositiveReported Sunday, AstraZeneca And Daiichi Sankyo's DATROWAY Extends Overall Survival By 5 Months And Reduces Progression Risk By 43% In Metastatic Triple-Negative Breast Cancer
📈 PositiveReported Sunday, Daiichi Sankyo And Merck's Raludotatug Deruxtecan Shows 50.5% Objective Response Rate In Recurrent Platinum-Resistant Ovarian, Primary Peritoneal Or Fallopian Tube Cancer
📈 PositiveTROPION-PanTumor03 Phase 2 Trial Shows That DATROWAY, Jointly Developed And Commercialized By Daiichi Sankyo And AstraZeneca, Reveals Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial; A Confirmed Objective Response Rate Of 68.2% And A Disease Control Rate Of 95.5% Was Observed In Previously Untreated, Cisplatin Ineligible Patients
📈 PositiveAstraZeneca And Daiichi Sankyo Report Phase 3 Results Showing Datroway's Superiority To Chemotherapy In First-Line Metastatic Triple Negative Breast Cancer
📈 PositiveAstraZeneca shares are trading higher after the company and Daiichi Sankyo announced its supplemental Biologics License Application for ENHERTU followed by paclitaxel, trastuzumab and pertuzumab has been accepted for review in the U.S. for the neoadjuvant treatment of adult patients with HER2 positive stage 2 or stage 3 breast cancer.
📈 PositiveDaiichi Sankyo And AstraZeneca's Breast Cancer Drug ENHERTU Accepted For FDA Review In Early-Stage HER2 Patients
📈 PositiveDaiichi Sankyo And AstraZeneca's ENHERTU Demonstrates Statistically Significant Improvement In Invasive Disease-Free Survival Versus T-DM1 In DESTINY-Breast05 Phase 3 Trial
📈 PositiveDaiichi Sankyo And AstraZeneca's ENHERTU Combination Shows 44% Risk Reduction Versus THP In HER2 Positive Metastatic Breast Cancer
📈 PositiveThe FDA Grants Breakthrough Therapy Designation To Merck And Daiichi Sankyo Partnered Ifinatamab Deruxtecan For Extensive-stage Small Cell Lung Cancer With Disease Progression On Or After Platinum-based Chemotherapy
📈 PositiveFrequently Asked Questions about DSNKY
What is DSNKY's current stock price?
What is the analyst price target for DSNKY?
What sector is Daiichi Sankyo Company, Limited in?
What is DSNKY's market cap?
Does DSNKY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to DSNKY for comparison